Aligos Therapeutics (ALGS) EBT (2021 - 2025)
Historic EBT for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$31.5 million.
- Aligos Therapeutics' EBT fell 6423.73% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.2 million, marking a year-over-year decrease of 1235.28%. This contributed to the annual value of -$130.9 million for FY2024, which is 5063.76% down from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' EBT is -$31.5 million, which was down 6423.73% from -$15.7 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' EBT registered a high of $43.1 million during Q1 2025, and its lowest value of -$82.1 million during Q4 2024.
- For the 5-year period, Aligos Therapeutics' EBT averaged around -$23.5 million, with its median value being -$22.9 million (2023).
- The largest annual percentage gain for Aligos Therapeutics' EBT in the last 5 years was 22380.09% (2025), contrasted with its biggest fall of 39862.86% (2025).
- Over the past 5 years, Aligos Therapeutics' EBT (Quarter) stood at -$37.8 million in 2021, then soared by 42.19% to -$21.8 million in 2022, then decreased by 27.87% to -$27.9 million in 2023, then tumbled by 194.12% to -$82.1 million in 2024, then skyrocketed by 61.67% to -$31.5 million in 2025.
- Its EBT stands at -$31.5 million for Q3 2025, versus -$15.7 million for Q2 2025 and $43.1 million for Q1 2025.